Galectin Therapeutics Inc
$ 4.05
0.50%
26 Dec - close price
- Market Cap 261,141,000 USD
- Current Price $ 4.05
- High / Low $ 4.19 / 3.90
- Stock P/E N/A
- Book Value -1.95
- EPS -0.59
- Next Earning Report 2026-03-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.87 %
- ROE -37.28 %
- 52 Week High 7.13
- 52 Week Low 0.94
About
Galectin Therapeutics Inc. (GALT) is a clinical-stage biopharmaceutical company headquartered in Norcross, Georgia, focusing on the development of novel therapies for fibrotic diseases, select cancers, and other severe medical conditions. Utilizing its proprietary technology based on galectin proteins, GALT is strategically targeting key pathways involved in disease progression and inflammation, which are critical for addressing significant unmet medical needs. With a robust pipeline and a strong commitment to advancing its therapeutic candidates towards FDA approval, Galectin Therapeutics aims to enhance treatment options for patients grappling with some of today's most challenging health issues.
Analyst Target Price
$11.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-14 | 2025-05-13 | 2025-03-27 | 2024-11-11 | 2024-08-13 | 2024-05-15 | 2024-03-29 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.13 | -0.12 | -0.1917 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 | -0.19 | -0.18 |
| Estimated EPS | -0.18 | -0.19 | -0.11 | -0.16 | -0.2 | -0.16 | -0.16 | -0.16 | -0.16 | -0.21 | -0.21 | -0.17 |
| Surprise | 0.05 | 0.07 | -0.0817 | -0.03 | 0.02 | -0.04 | -0.03 | 0 | -0.08 | 0.06 | 0.02 | -0.01 |
| Surprise Percentage | 27.7778% | 36.8421% | -74.2727% | -18.75% | 10% | -25% | -18.75% | 0% | -50% | 28.5714% | 9.5238% | -5.8824% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.18 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GALT
2025-12-27 04:09:29
Pomerantz LLP is investigating potential claims against Galectin Therapeutics Inc. (NASDAQ:GALT) on behalf of investors following a significant stock price drop. This investigation was prompted by the FDA's written response to Galectin's Type C meeting request, which indicated unresolved key aspects for their clinical trial design, leading to a 28.9% decrease in Galectin's stock on December 19, 2025. Investors are advised to contact the law firm for more information regarding joining the class action.
2025-12-27 04:09:14
Pomerantz LLP is investigating potential securities fraud claims against Galectin Therapeutics Inc. (NASDAQ: GALT) following a significant drop in its stock price. This decline occurred after the company announced that the FDA converted their Type C meeting request to a written response, indicating unresolved key aspects of their belapectin clinical trial design. Investors are encouraged to contact Pomerantz LLP to join the class action.
2025-12-25 00:09:19
Pomerantz LLP is investigating potential securities fraud claims against Galectin Therapeutics Inc. (NASDAQ:GALT) after the company announced unresolved issues with the FDA regarding its clinical trial design for belapectin. Following this news on December 19, 2025, Galectin's stock price dropped by 28.9%, leading to the investigation on behalf of investors.
2025-12-24 05:09:19
Kevin D. Freeman, a director at Galectin Therapeutics (NASDAQ:GALT), recently bought 5,500 shares for $19,514, bringing his direct ownership to 55,269 shares. This purchase occurred despite a recent 35% stock drop for GALT, though the stock is up over 350% year-over-year. InvestingPro analysis suggests the stock is currently overvalued, despite a high analyst target price of $11, and the company faces profitability and short-term liquidity challenges.
2025-12-24 05:08:38
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors of Galectin Therapeutics Inc. (NASDAQ: GALT). This investigation follows a significant 28.9% drop in Galectin's stock price after the U.S. Food and Drug Administration (FDA) provided a written response, rather than an in-person meeting, regarding the development program for its investigational drug, belapectin. While there is alignment on the patient population for a registration trial, key aspects of the trial design remain unresolved, prompting the firm's probe into potential unlawful business practices.
2025-12-24 05:08:38
Eldred Kary, a director at Galectin Therapeutics Inc. (NASDAQ:GALT), purchased 700 shares of common stock for $2,611 on December 23, 2025. This insider acquisition comes after a 35% drop in GALT's share price over the past week, despite a significant 352.8% return over the past year. The company is also actively engaging with the FDA regarding its MASH cirrhosis treatment, with the potential for a Type C meeting to resolve trial design issues.
